on May 2,
INTRODUCTION
Tumor immunotherapy is aimed at inducing immune responses to destroy tumor cells (1) . However, tumors usually behave as poorly immunogenic for T-cells, because as opposed to professional antigen presenting cells such as dendritic cells (DC), they express low levels of antigens, MHC and co-stimulatory molecules (2) . Moreover, unlike danger signals associated with pathogens, such as toll-like receptor (TLR) ligands, or inflammatory signals (cytokines or CD40L expressed on activated CD4 Tcells), which induce DC maturation, tumor cells do not release immunogenic danger signals, unless they are submitted to radio-or chemotherapy (3) . DC maturation, which involves upregulation of co-stimulatory, adhesion and antigen presenting molecules as well as the production of cytokines and chemokines, is necessary for correct T-cell activation (4) . Therefore, to overcome the low tumor immunogenicity, new therapeutic strategies are based on the use of adjuvants (molecules able to induce DC maturation) with or without exogenously added tumor antigens, which will activate DC to properly present tumor antigens to T-cells and trigger their effector functions (5) . With this aim, a great effort has been made to characterize DC-activating ligands to be used as adjuvant molecules, due to their immunostimulatory and/or targeting properties, and thus avoid the use of microorganisms containing undefined adjuvant mixtures (6) . These activating molecules have been shown to increase the immunostimulatory properties of DC by signalling through different activation pathways, and in some cases, synergistic effects have been observed (7) (8) (9) (10) (11) . Thus, development of therapeutic strategies based on the use of molecularly defined components is a main goal in tumor immunology. We had previously shown that administration of an adjuvant mixture containing the TLR3 ligand poly(I:C) and agonistic anti-CD40 antibodies, together with ovalbumin (OVA) as tumor antigen, protected mice against the growth of E.G7-OVA thymoma and rejected established tumors in this model (12) . B16 melanoma cell lines (13) are poorly immunogenic tumors which have many characteristics of tumors found in patients and consequently, may be a good model to develop immunotherapeutic strategies with potential clinical applications. Several approaches have been used to induce immune responses able to reject B16 melanoma. They are based on the use of DC pulsed or expressing different types of antigens (14) (15) (16) or complex immunogens such as recombinant viruses, bacteria or virus-like particles which contain many DCactivating signals (17) (18) (19) . All these data prompted us to develop an immunotherapeutic strategy to treat B16-OVA established tumors using combinations of adjuvants and antigens. We report below the anti-tumor efficacy of this strategy, together with the immunological mechanisms responsible of its outcome. 
MATERIALS AND METHODS

Reagents
Peptides OVA(257-264) and TRP-2(180-188) were synthesized in an automatic APEX 396 multiple peptide synthesizer (Aapptec LLC; Louisville, KY). Peptide identity was confirmed by mass spectrometry and their purity was >95%, as determined by HPLC.
OVA protein was purchased from Sigma Aldrich (Madrid, Spain). Proteins containing the extra domain A from fibronectin EDA and EDA-OVA were produced as described (20) . Endotoxin levels in these proteins were below 0.2 EU/μg protein as analyzed using the LAL test (Cambrex, Walkersville, MD). Imiquimod was used in vivo as Aldara™ cream (Meda Pharma; Madrid, Spain) and for in vitro experiments was obtained from Invivogen (San Diego, CA). Poly(I:C) was obtained from Amersham (Barcelona, Spain) and agonistic anti-CD40 antibody was purified from FGK45.5 hybridoma cells as decribed (12) .
Mice
Female C57BL/6 mice (6-8 weeks-old) (Harlan; Barcelona, Spain) were maintained in pathogen-free conditions and treated according to guidelines of our institution, after study approval by the review committee.
Cell lines
Parental EL-4 thymoma cells, OVA-transfected E.G7-OVA cells and the NK-sensitive cell line YAC-1 were purchased from American Type Culture Collection (Manassas, VA) and were grown as described (21) . Cells were thawed and passaged according to ATCC guidelines for less than 6 months from the time they were received or thawed. 
Ex vivo analysis of DC
Mice bearing 4-5 mm tumors (n=5) received a single administration of different adjuvant combinations as described above, and one day later tumors or tumor-draining lymph nodes were removed, pooled and DC analyzed directly by flow cytometry or by real-time PCR after purification with anti-CD11c-conjugated magnetic beads (Miltenyi;
BergischGladbach, Germany).
Analysis by real-time PCR
Total RNA extraction from tumor cell lines or dendritic cells and real-time PCR were performed as described (23) , using primers shown in Supplementary Table S1 . Results were normalized according to β-actin. The amount of each transcript was expressed by the formula: 2 ΔCt (ΔCt = Ct(β-actin)-Ct(gene)).
ELISPOT
Cells producing IFN-γ were enumerated by ELISPOT assays using a kit from BDBiosciences (San Diego, CA) as described (12) . For T-cell responses, splenocytes were 
Statistical analysis
Survival curves of animals treated with different protocols were plotted according to the Kaplan-Meier method and were compared using the log-rank test. Immune responses were analyzed using nonparametric Kruskal-Wallis and Mann-Whitney U tests. 
RESULTS
Immunotherapy based only on adjuvant administration has a poor effect on B16-OVA tumor bearing mice, inducing innate but not adaptive immunity
We have previously reported that a single prophylactic administration of adjuvant molecules poly(I:C) and agonistic anti-CD40 antibodies plus OVA protein induced potent T-cell responses which protected 100% of mice from the growth of subcutaneous E.G7-OVA tumors (12) . When this protocol was applied to the B16-OVA melanoma model no differences in tumor growth and survival were observed between control and Rejection of E.G7-OVA tumors after administration of poly(I:C) plus anti-CD40 was associated with the induction of innate and adaptive immunity (12) . Therefore, we studied these parameters when using Imiquimod and anti-CD40 as adjuvants. Naïve mice received a single administration of Imiquimod plus anti-CD40 and NK cell activity was studied by measuring CD69 upregulation on CD3 -NK1.1 + cells and IFN-γ production against the NK-sensitive YAC-1 cell line. A high activity in both functions was found at 24 h ( Figure 1B) . Regarding spleen DC, a clear upregulation of CD86 was observed ( Figure 1C ). Finally, analysis of serum cytokines showed a peak for IL-12 at 6 h (226 pg/ml), whereas TNF-α levels grew until 48 h (625 pg/ml).
Analysis of anti-tumor adaptive immune responses was carried out in tumor-bearing mice, untreated or treated with Imiquimod plus anti-CD40. None of these groups displayed IFN-γ production against the CD8 T-cell epitope OVA(257-264) or OVA protein in ELISPOT assays ( Figure 1D ). These results suggest that administration of adjuvants to B16-OVA tumor-bearing mice induces innate but not adaptive immunity.
Combination of adjuvants Imiquimod and anti-CD40 with the tumor antigen OVA, induces adaptive immunity with better antitumor effects
The lack of adaptive immunity in B16-OVA-tumor bearing mice treated with adjuvants alone led us to hypothesize that inclusion of an antigen together with adjuvants might be able to induce T-cell responses. Indeed, repeated administration of OVA together with poly(I:C) and anti-CD40 enhanced E.G7-OVA tumor rejection from 35% to 100% (12) . Figure 2D ). Thus, a protocol which combines the tumor antigen with double-adjuvant mixtures induces Tcell responses, delays tumor growth during treatment period and some days beyond, but does not lead to tumor rejection.
Multiple adjuvant combination and antigen targeting enhances innate immunity
The poor but significant effect that antigen plus adjuvant administration had on tumor growth suggested that new strategies inducing enhanced T-cell responses might be more 
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MAC vs. OVA + Imiquimod + anti-CD40). When adjuvants were administered to tumor-bearing mice, MAC and EDA + MAC were the most potent combinations (P<0.05; MAC or EDA + MAC vs. remaining groups) ( Figure 3C ).
Multiple adjuvant combination and antigen targeting induces polyfunctional high avidity T-cell responses
Analysis of adaptive immunity in naïve mice immunized with the different combinations was done by ELISPOT assays which measured the number of CD8 and CAN-10-3259 overcome the poor efficacy of these protocols, we used a multiple adjuvant combination containing Imiquimod, poly(I:C), anti-CD40 as well as EDA coupled to OVA, which acts as adjuvant through TLR4 and targets the antigen to antigen presenting cells. In this case, tumor rejection was observed in half of treated animals, associated with a clear improvement of the immune response induced by treatment. A synergy between different adjuvants has been reported in vitro and in vivo for DC (7, 8, 10, 11, 24) , mainly for those receptors which do not share signalling pathways. Thus, we used poly(I:C), which binds to TLR3 (25) and triggers the TRIF pathway, Imiquimod, which uses TLR7 with Myd88 as adaptor molecule (26), anti-CD40, which triggers a TRAFdependent pathway (27), and EDA, able to bind to TLR4, a receptor connected to the TRIF and Myd88 pathways (28) 
